Jump to content

Farglitazar

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Cyberfan195 (talk | contribs) at 01:14, 25 January 2020 (References: adding it to GlaxoSmithKline brands.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Farglitazar
Clinical data
Pregnancy
category
  • N/A
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • N-(o-Benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC34H30N2O5
Molar mass546.623 g·mol−1
3D model (JSmol)
  • O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
  • InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ☒N
  • Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ☒N
 ☒NcheckY (what is this?)  (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed. It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy.[1] After reaching phase III for type 2 diabetes, further development was discontinued.[2][3]

References

  1. ^ McHutchison, John; Goodman, Zachary; Patel, Keyur; Makhlouf, Hala; Rodriguez–Torres, Maribel; Shiffman, Mitchell; Rockey, Don; Husa, Petr; Chuang, Wan–Long; Levine, Robert; Jonas, Mark; Theodore, Dickens; Brigandi, Richard; Webster, Alison; Schultz, Margaret; Watson, Helen; Stancil, Britt; Gardner, Stephen (2010). "Farglitazar Lacks Antifibrotic Activity in Patients with Chronic Hepatitis C Infection". Gastroenterology. 138 (4): 1365–1373.e2. doi:10.1053/j.gastro.2009.12.003. PMID 20004661.
  2. ^ "Farglitazar". Adis Insight.
  3. ^ "Farglitazar". pharmacodia.com.